Experimental pancreatic cancer pill helps improve survival in late-stage study

A novel oral drug nearly doubles survival time in late-stage pancreatic cancer trial, offering a potential breakthrough for a notoriously difficult-to-treat disease. | Contesto: cronaca

Punti chiave

• Experimental pancreatic cancer pill helps improve survival in late-stage study

Contesto

An experimental oral drug has nearly doubled survival time for patients with advanced pancreatic cancer in a pivotal late-stage clinical trial, its developer announced Monday. Patients receiving the once-daily pill, daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for those on standard intravenous chemotherapy. The data from Revolution Medicines' study marks a significant and eagerly awaited result in oncology, offering a glimmer of hope for a disease with one of the lowest survival rates among all major cancers. The trial results represent a potential paradigm shift in treating metastatic pancreatic cancer, where progress has been agonizingly slow. The current standard of care, cytotoxic chemotherapy, is burdensome, requiring frequent clinic visits for infusions and often causing severe side effects that drastically impact quality of life. Daraxonrasib's performance not only suggests a dramatic extension of life but also points to the possibility of a more manageable treatment regimen administered as a simple pill. The drug also demonstrated an improvement in progression-free survival, meaning patients lived longer without their cancer worsening. Pancreatic cancer's lethality stems from its aggressive biology and frequent late diagnosis, with most patients discovered at an advanced, inoperable stage. For decades, treatment options have offered only marginal benefits, and the five-year survival rate for metastatic disease remains in the single digits. The stark survival gap highlighted in this trial—13.2 months versus 6.7—is among the most substantial improvements seen in recent memory for this patient population. The data is particularly compelling because it comes from a Phase 3 trial, the final and most rigorous stage of clinical testing before regulatory submission. Daraxonrasib belongs to a class of drugs known as RAS inhibitors, targeting a family of proteins that are mutated in approximately 90% of pancreatic cancers. The decades-long scientific quest to drug the so-called "undruggable" RAS pathway has seen recent breakthroughs, primarily in lung cancer. This trial success is the first clear signal that the same strategy can be...

Lettura DEO

Decisione di validazione: publish

Risk score: 0.1

Il testo è stato ricostruito dai dati editoriali disponibili senza aggiungere fatti non presenti nel record sorgente.

Indicatore di affidabilità

Verificata — Alta confidenza. Fonti affidabili confermano la notizia.

Il sistema a semaforo

Ogni articolo su DEO include un indicatore di affidabilità:

• 🟢 Verificata — Alta confidenza. Fonti affidabili confermano la notizia.
• 🟡 In evoluzione — Confidenza moderata. Alcuni dettagli potrebbero ancora cambiare.
• 🔴 Contestata — Bassa confidenza. Fonti in conflitto o incertezze rilevanti.

Questo sistema esiste perché chi legge merita di sapere non solo cosa è successo, ma anche quanto la notizia è solida.

Categoria: cronaca